Literature DB >> 34083719

Hemodialysis exacerbates proteolytic imbalance and pro-fibrotic platelet dysfunction.

Aaron J Velasquez-Mao1, Mark A Velasquez2, Zhengxiong Hui2, Denise Armas-Ayon2, Jingshen Wang3, Moriel H Vandsburger4.   

Abstract

Multi-organ fibrosis among end stage renal disease (ESRD) patients cannot be explained by uremia alone. Despite mitigation of thrombosis during hemodialysis (HD), subsequent platelet dysfunction and tissue dysregulation are less understood. We comprehensively profiled plasma and platelets from ESRD patients before and after HD to examine HD-modulation of platelets beyond thrombotic activation. Basal plasma levels of proteolytic regulators and fibrotic factors were elevated in ESRD patients compared to healthy controls, with isoform-specific changes during HD. Platelet lysate (PL) RNA transcripts for growth and coagulative factors were elevated post-HD, with upregulation correlated to HD vintage. Platelet secretome correlations to plasma factors reveal acutely induced pro-fibrotic platelet phenotypes in ESRD patients during HD characterized by preferentially enhanced proteolytic enzyme translation and secretion, platelet contribution to inflammatory response, and increasing platelet dysfunction with blood flow rate (BFR) and Vintage. Compensatory mechanisms of increased platelet growth factor synthesis with acute plasma matrix metalloproteinase (MMP) and tissue inhibitor of MMPs (TIMP) increases show short-term mode-switching between dialysis sessions leading to long-term pro-fibrotic bias. Chronic pro-fibrotic adaptation of platelet synthesis were observed through changes in differential secretory kinetics of heterogenous granule subtypes. We conclude that chronic and acute platelet responses to HD contribute to a pro-fibrotic milieu in ESRD.

Entities:  

Year:  2021        PMID: 34083719     DOI: 10.1038/s41598-021-91416-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  41 in total

1.  Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.

Authors:  P B Mark; N Johnston; B A Groenning; J E Foster; K G Blyth; T N Martin; T Steedman; H J Dargie; A G Jardine
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

2.  Where is psychiatry in primary care medical training?

Authors:  R J Goldberg; T N Wise
Journal:  Psychosomatics       Date:  1985-11       Impact factor: 2.386

Review 3.  Oxidative stress - chronic kidney disease - cardiovascular disease: A vicious circle.

Authors:  Verdiana Ravarotto; Francesca Simioni; Elisa Pagnin; Paul A Davis; Lorenzo A Calò
Journal:  Life Sci       Date:  2018-08-31       Impact factor: 5.037

Review 4.  The hallmarks of mitochondrial dysfunction in chronic kidney disease.

Authors:  Daniel L Galvan; Nathanael H Green; Farhad R Danesh
Journal:  Kidney Int       Date:  2017-11       Impact factor: 10.612

5.  Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease.

Authors:  Puya G Yazdi; Hamid Moradi; Jia-Ying Yang; Ping H Wang; Nasratola D Vaziri
Journal:  Int J Clin Exp Med       Date:  2013-08-01

Review 6.  Evolving concepts in the pathogenesis of uraemic cardiomyopathy.

Authors:  Xiaoliang Wang; Joseph I Shapiro
Journal:  Nat Rev Nephrol       Date:  2019-03       Impact factor: 28.314

Review 7.  Management of Heart Failure in Advancing CKD: Core Curriculum 2018.

Authors:  Andrew A House
Journal:  Am J Kidney Dis       Date:  2018-02-23       Impact factor: 8.860

Review 8.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.

Authors:  Lesley A Inker; Brad C Astor; Chester H Fox; Tamara Isakova; James P Lash; Carmen A Peralta; Manjula Kurella Tamura; Harold I Feldman
Journal:  Am J Kidney Dis       Date:  2014-03-16       Impact factor: 8.860

Review 9.  Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?

Authors:  Ashwin Radhakrishnan; Luke C Pickup; Anna M Price; Jonathan P Law; Nicola C Edwards; Richard P Steeds; Charles J Ferro; Jonathan N Townend
Journal:  Heart       Date:  2019-06-25       Impact factor: 5.994

Review 10.  Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation.

Authors:  Kerstin Benz; Karl-Friedrich Hilgers; Christoph Daniel; Kerstin Amann
Journal:  Int J Nephrol       Date:  2018-08-13
View more
  1 in total

1.  Cyclical depressurization degranulates platelets in an agonist-free mechanism of platelet activation.

Authors:  Aaron J Velasquez-Mao; Mark Velasquez; Moriel H Vandsburger
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.